Loading
Led VIALE-A, which made venetoclax plus azacitidine the standard for older patients with acute myeloid leukaemia.
Courtney DiNardo was principal investigator of VIALE-A, which showed venetoclax plus azacitidine improves survival and doubles remission rates in older adults with AML unfit for intensive chemotherapy, replacing hypomethylating agents alone and reshaping AML treatment globally. She led the first-in-human ivosidenib trial and co-led AGILE (ivosidenib plus azacitidine in IDH1-mutant AML). Her work continues on venetoclax-based triplets and measurable residual disease.
AGILE showed that for the roughly 6-10% of AML patients with an IDH1 mutation, a targeted doublet produces survival in the range of two years, an outcome previously unimaginable in unfit patients. Ivosidenib-azacitidine is approved and is one option alongside venetoclax-azacitidine for these patients. Which regimen, or triplet, is best for IDH1-mutated disease has not been settled by a randomised trial.
VIALE-A turned a palliative regimen into one that produces remission in two-thirds of older AML patients and is now the reference treatment for anyone not fit for intensive chemotherapy. It shifted the field towards lower-intensity targeted combinations and opened the door to adding FLT3, IDH and menin inhibitors to the backbone. Cure remains uncommon and most patients relapse within two years.
Shares BCL-2, Venetoclax, Acute myeloid leukaemia and the tags aml, venetoclax.
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, MD Anderson Cancer Center, Acute myeloid leukaemia and the tag aml.
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, VIALE-A, Venetoclax, Acute myeloid leukaemia.
Shares IDH1 / IDH2, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Acute myeloid leukaemia and the tag aml.
Shares BCL-2, Venetoclax and the tag venetoclax.
Shares BCL-2, Venetoclax and the tag venetoclax.
Shares BCL-2, Venetoclax and the tag venetoclax.
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, VIALE-A, Venetoclax, Acute myeloid leukaemia.